How many patients have accessed the COVID-19 prevention drug, Evusheld, broken down by NHS board.

Evusheld ® was developed and tested before the emergence of the Omicron variant. The RAPID C-19 group and the COVID-19 UK expert panel have considered a full range of evidence, including clinical trial data, in vitro (in the lab) analysis and observational studies, and have advised that there is insufficient evidence available to support procurement and deployment of Evusheld ®. As a result, there is currently no established NHS supply arrangement for Evusheld ® in the UK.
The National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC, as part of Healthcare Improvement Scotland (HIS)) have agreed to maintain the collaboration that started through RAPID C-19 by collaborating on a single health technology appraisal (STA) of Evusheld ® for the prevention of COVID-19. NICE and the SMC will produce separate guidance and advice documents, but the recommendations will be aligned. Draft guidance was published on 16 February 2023, and does not recommend its use. Final guidance on the STA is expected to be published in June 2023.